Atlas Trials

Ph2 NK Cell Enriched DCIs w/wo RLR9 Agonist, DUK-CPG-001 From Donors Following Allogeneic SCT

Clinical trial NCT02452697 · UNKNOWN

Trial details

NCT number
NCT02452697
Sponsor
Cristina Gasparetto
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Myeloid MalignanciesLymphoid Malignancies
Start date
2016-06-08
Primary completion
2022-07-23
Enrollment
36

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.